Eccogene, a China-based clinical stage biopharmaceutical company, announced on Monday that it has received approval from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application to start phase one trial of its thyroid hormone receptor agonist ECC4703 in the United States.
The study is intended to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ECC4703 in healthy participants and subjects with elevated LDL.
ECC4703 was discovered from the company's internal drug discovery platform and is a beta-selective, liver targeting THR full agonist. The company said that it has showcased superiority in pre-clinical studies over partial agonist MGL-3196 and has also indicated robust efficacy in pre-clinical models of non-alcoholic steatohepatitis (NASH) and dyslipidemia.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial